Are Amyloids Infectious?

  • Rodrigo Morales
  • Baian Chen
  • Claudio Soto


Misfolding and aggregation of proteins is the main feature of a group of maladies which include most of neurodegenerative diseases (such as Alzheimer’s, Parkinson’s, Huntington’s, and prion diseases), as well as several systemic amyloidosis. Among them, prion disease are the only one known to be infectious. Current evidence shows that the infectious agent in prion diseases is the misfolded protein and that the molecular mechanisms responsible for transmissibility are very similar to the process of amyloid formation in all protein misfolding disorders (PMDs). In this chapter, we discuss the theoretical and experimental evidences suggesting the possible infectious nature of several PMDs.


Amyotrophic Lateral Sclerosis Prion Protein Misfolded Protein Prion Disease Bovine Spongiform Encephalopathy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



We thank Dr. Kristi Green for critical review of the manuscript. This manuscript was supported by a grant from the CART Foundation to Claudio Soto.


  1. 1.
    Soto C (2001) Protein misfolding and disease; protein refolding and therapy. FEBS Lett 498:204–207PubMedCrossRefGoogle Scholar
  2. 2.
    Chiti F and Dobson CM (2006) Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem 75:333–366PubMedCrossRefGoogle Scholar
  3. 3.
    Carrell RW (2005) Cell toxicity and conformational disease. Trends Cell Biol 15:574–580PubMedCrossRefGoogle Scholar
  4. 4.
    Soto C, Estrada L, Castilla J (2006) Amyloids, prions and the inherent infectious nature of misfolded protein aggregates. Trends Biochem Sci 31:150–155PubMedCrossRefGoogle Scholar
  5. 5.
    Walker LC, Levine H III, Mattson MP, Jucker M (2006) Inducible proteopathies. Trends Neurosci 29:438–443PubMedCrossRefGoogle Scholar
  6. 6.
    Soto C (2003) Unfolding the role of protein misfolding in neurodegenerative diseases. Nature Rev Neurosci 4:49–60CrossRefGoogle Scholar
  7. 7.
    Glenner GG (1980) Amyloid deposits and amyloidosis. The beta-fibrilloses (first of two parts). N Engl J Med 302:1283–1292PubMedGoogle Scholar
  8. 8.
    Blake CC, Serpell LC, Sunde M, Sandgren O, Lundgren E (1996) A molecular model of the amyloid fibril. Ciba Found Symp 199:6–15PubMedGoogle Scholar
  9. 9.
    Hardy J, Gwinn-Hardy K (1998) Genetic classification of primary neurodegenerative disease. Science 282:1075–1079PubMedCrossRefGoogle Scholar
  10. 10.
    Rockenstein E, Crews L, Masliah E (2007) Transgenic animal models of neurodegenerative diseases and their application to treatment development. Adv Drug Deliv Rev 59:1093–1102PubMedCrossRefGoogle Scholar
  11. 11.
    Canevari L, Abramov AY, Duchen MR (2004) Toxicity of amyloid beta peptide: tales of calcium, mitochondria, and oxidative stress. Neurochem Res 29:637–650PubMedCrossRefGoogle Scholar
  12. 12.
    Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid beta-peptide. Nat Rev Mol Cell Biol 8:101–112PubMedCrossRefGoogle Scholar
  13. 13.
    Glabe CG (2006) Common mechanisms of amyloid oligomer pathogenesis in degenerative disease. Neurobiol Aging 27:570–557PubMedCrossRefGoogle Scholar
  14. 14.
    Caughey B, Lansbury PT (2003) Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci 26:267–298PubMedCrossRefGoogle Scholar
  15. 15.
    Collinge J (2001) Prion diseases of humans and animals: their causes and molecular basis. Annu Rev Neurosci 24:519–550PubMedCrossRefGoogle Scholar
  16. 16.
    Cullie J, Chelle PL (1939) Experimental transmission of trembling to the goat. Comptes Rendus des Seances de l’Academie des Sciences 208:1058–1160Google Scholar
  17. 17.
    Aguzzi A, Polymenidou M (2004) Mammalian prion biology: one century of evolving concepts. Cell 116:313–327PubMedCrossRefGoogle Scholar
  18. 18.
    Soto C, Castilla J (2004) The controversial protein-only hypothesis of prion propagation. Nat Med 10:S63–S67PubMedCrossRefGoogle Scholar
  19. 19.
    Prusiner SB (1998) Prions. Proc Natl Acad Sci USA 95:13363–13383PubMedCrossRefGoogle Scholar
  20. 20.
    Prusiner SB (1982) Novel proteinaceous infectious particles cause scrapie. Science 216:136–144PubMedCrossRefGoogle Scholar
  21. 21.
    Bueler H, Aguzzi A, Sailer A, (1993) Mice devoid of PrP are resistant to scrapie. Cell 73:1339–1347PubMedCrossRefGoogle Scholar
  22. 22.
    Fischer M, Rülicke T, Raeber A, (1996) Prion protein (PrP) with amino-proximal deletions restoring susceptibility of PrP knockout mice to scrapie. EMBO J 15:1255–1264PubMedGoogle Scholar
  23. 23.
    Groschup MH, Buschmann A (2008) Rodent models for prion diseases. Vet Res 39:32.PubMedCrossRefGoogle Scholar
  24. 24.
    Caughey B (2003) Prion protein conversions: insight into mechanisms, TSE transmission barriers and strains. Br Med Bull 66:109–120PubMedCrossRefGoogle Scholar
  25. 25.
    Soto C, Saborio GP, Anderes L (2002) Cyclic amplification of protein misfolding: application to prion-related disorders and beyond. Trends Neurosci 25:390–394PubMedCrossRefGoogle Scholar
  26. 26.
    Legname G, Baskakov IV, Nguyen HO, (2004) Synthetic mammalian prions. Science 305:673–676PubMedCrossRefGoogle Scholar
  27. 27.
    Saborio GP, Permanne B, Soto C (2001) Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding. Nature 411:810–813PubMedCrossRefGoogle Scholar
  28. 28.
    Castilla J, Saá P, Hetz C, Soto C (2005) In vitro generation of infectious scrapie prions. Cell 121:195–206PubMedCrossRefGoogle Scholar
  29. 29.
    Jarrett JT, Lansbury PT Jr (1993) Seeding “one-dimensional crystallization” of amyloid: a pathogenic mechanism in Alzheimer’s disease and scrapie?. Cell 73:1055–1058PubMedCrossRefGoogle Scholar
  30. 30.
    Walker LC, Bian F, Callahan MJ, (2002) Modeling Alzheimer’s disease and other proteopathies in vivo: is seeding the key?. Amino Acids 23:87–93PubMedCrossRefGoogle Scholar
  31. 31.
    Gajdusek DC (1994) Nucleation of amyloidogenesis in infectious and noninfectious amyloidoses of brain. Ann NY Acad Sci 724:173–190PubMedCrossRefGoogle Scholar
  32. 32.
    Harper JD, Lansbury PT Jr (1997) Models of amyloid seeding in Alzheimer’s disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu Rev Biochem 66:385–407PubMedCrossRefGoogle Scholar
  33. 33.
    Krebs MR, Morozova-Roche LA, Daniel K, Robinson CV, Dobson CM (2004) Observation of sequence specificity in the seeding of protein amyloid fibrils. Protein Sci 13:1933–1938PubMedCrossRefGoogle Scholar
  34. 34.
    Gajdusek DC, Gibbs CJ, Alpers M (1966) Experimental transmission of a Kuru-like syndrome to chimpanzees. Nature 209:794–796PubMedCrossRefGoogle Scholar
  35. 35.
    Sigurdsson EM, Wisniewski T, Frangione B (2002) Infectivity of amyloid diseases. Trends Mol Med 8:411–413PubMedCrossRefGoogle Scholar
  36. 36.
    Baker HF, Ridley RM, Duchen LW, Crow TJ, Bruton CJ (1994) Induction of beta (A4)-amyloid in primates by injection of Alzheimer’s disease brain homogenate. Comparison with transmission of spongiform encephalopathy. Mol Neurobiol 8:25–39Google Scholar
  37. 37.
    Goudsmit J, Morrow CH, Asher DM, (1980) Evidence for and against the transmissibility of Alzheimer disease. Neurology 30:945–950PubMedGoogle Scholar
  38. 38.
    Morales R, Abid K, Soto C (2007) The prion strain phenomenon: molecular basis and unprecedented features. Biochim Biophys Acta 1772:681–691PubMedGoogle Scholar
  39. 39.
    Duff K (2001) Transgenic mouse models of Alzheimer’s disease: phenotype and mechanisms of pathogenesis. Biochem Soc Symp 67:195–202.PubMedGoogle Scholar
  40. 40.
    Kane MD, Lipinski WJ, Callahan MJ, (2000) Evidence for seeding of beta-amyloid by intracerebral infusion of Alzheimer brain extracts in beta-amyloid precursor protein-transgenic mice. J Neurosci 20:3606–3611PubMedGoogle Scholar
  41. 41.
    Walker LC, Callahan MJ, Bian F, (2002) Exogenous induction of cerebral beta-amyloidosis in betaAPP-transgenic mice. Peptides 23:1241–1247PubMedCrossRefGoogle Scholar
  42. 42.
    Meyer-Luehmann M, Coomaraswamy J, Bolmont T, (2006) Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science 313:1781–1784PubMedCrossRefGoogle Scholar
  43. 43.
    Sipe JD (2000) Serum amyloid A: from fibril to function. Current status. Amyloid 7:10–12Google Scholar
  44. 44.
    Buxbaum JN (2004) The systemic amyloidoses. Curr Opin Rheumatol 16:67–75PubMedCrossRefGoogle Scholar
  45. 45.
    Anders RF, Natvig JB, Michaelsen TE, Husby G (1975) Isolation and characterization of amyloid-related serum protein SAA as a low molecular weight protein. Scand J Immunol 4:397–401PubMedCrossRefGoogle Scholar
  46. 46.
    De Beer FC, Mallya RK, Fagan EA, Lanham JG, Hughes GR, Pepys MB (1982) Serum amyloid-A protein concentration in inflammatory diseases and its relationship to the incidence of reactive systemic amyloidosis. Lancet 2:231–234PubMedCrossRefGoogle Scholar
  47. 47.
    Sipe JD, Colten HR, Goldberger G, (1985) Human serum amyloid A (SAA): biosynthesis and postsynthetic processing of preSAA and structural variants defined by complementary DNA. Biochemistry 24:2931–2936PubMedCrossRefGoogle Scholar
  48. 48.
    Kisilevsky R, Boudreau L (1983) Kinetics of amyloid deposition. I. The effects of amyloid-enhancing factor and splenectomy. Lab Invest 48:53–59Google Scholar
  49. 49.
    Ganowiak K, Hultman P, Engstrom U, Gustavsson A, Westermark P (1994) Fibrils from synthetic amyloid-related peptides enhance development of experimental AA-amyloidosis in mice. Biochem Biophys Res Commun 199:306–312PubMedCrossRefGoogle Scholar
  50. 50.
    Lundmark K, Westermark GT, Nyström S, Murphy CL, Solomon A, Westermark P (2002) Transmissibility of systemic amyloidosis by a prion-like mechanism. Proc Natl Acad Sci USA 99:6979–6984PubMedCrossRefGoogle Scholar
  51. 51.
    Higuchi K, Naiki H, Kitagawa K, (1995) Apolipoprotein A-II gene and development of amyloidosis and senescence in a congenic strain of mice carrying amyloidogenic ApoA-II. Lab Invest 72:75–82PubMedGoogle Scholar
  52. 52.
    Higuchi K, Naiki H, Kitagawa K, Hosokawa M, Takeda T (1991) Mouse senile amyloidosis. ASSAM amyloidosis in mice presents universally as a systemic age-associated amyloidosis. Virchows Arch B Cell Pathol Incl Mol Pathol 60:231–238Google Scholar
  53. 53.
    Xing Y, Higuchi K (2002) Amyloid fibril proteins. Mech Ageing Dev 123:1625–1636PubMedCrossRefGoogle Scholar
  54. 54.
    Higuchi K, Kogishi K, Wang J, (1998) Fibrilization in mouse senile amyloidosis is fibril conformation-dependent. Lab Invest 78:1535–1542PubMedGoogle Scholar
  55. 55.
    Xing Y, Nakamura A, Chiba T, (2001) Transmission of mouse senile amyloidosis. Lab Invest 81:493–499PubMedGoogle Scholar
  56. 56.
    Xing Y, Nakamura A, Korenaga T, (2002) Induction of protein conformational change in mouse senile amyloidosis. J Biol Chem 277:33164–33169PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Rodrigo Morales
    • 1
  • Baian Chen
    • 1
  • Claudio Soto
    • 1
  1. 1.Protein Misfolding Disorders Laboratory, George and Cynthia Mitchell Center for Neurodegenerative diseasesDepartment of Neurology, University of Texas Medical Branch

Personalised recommendations